MD Magazine: Condition Center: Rheumatoid Arthritis Copyright (c) 2017 Intellisphere, LLC. All rights reserved. http://www.mdmag.com/conditions/rheumatoid-arthritis-resources/rss Rheumatoid Arthritis en-us Wed, 21 Feb 2018 17:01:44 +0000 FDA Accepts BLA for Novartis Adalimumab Biosimilar http://www.mdmag.com/medical-news/fda-accepts-bla-for-novartis-adalimumab-biosimilar http://www.mdmag.com/medical-news/fda-accepts-bla-for-novartis-adalimumab-biosimilar Tue, 16 Jan 2018 15:22:00 +0000 Upadacitinib Shows Positive Rheumatoid Arthritis Study Results http://www.mdmag.com/medical-news/upadacitinib-shows-positive-rheumatoid-arthritis-study-results http://www.mdmag.com/medical-news/upadacitinib-shows-positive-rheumatoid-arthritis-study-results Wed, 20 Dec 2017 18:17:00 +0000 Understanding the Pathophysiology of Crohn's Disease http://www.mdmag.com/insights/crohns-disease/understanding-the-pathophysiology-of-crohns-disease http://www.mdmag.com/insights/crohns-disease/understanding-the-pathophysiology-of-crohns-disease Fri, 01 Dec 2017 20:04:00 +0000 Adalimumab Prolonged Dosing Regimen Proves Safe for RA http://www.mdmag.com/medical-news/adalimumab-prolonged-dosing-regimen-proves-safe-for-ra http://www.mdmag.com/medical-news/adalimumab-prolonged-dosing-regimen-proves-safe-for-ra Fri, 29 Sep 2017 11:00:00 +0000 FDA Issues Response Letter to Janssen for RA Therapy Sirukumab http://www.mdmag.com/medical-news/fda-issues-response-letter-to-janssen-for-ra-therapy-sirukumab http://www.mdmag.com/medical-news/fda-issues-response-letter-to-janssen-for-ra-therapy-sirukumab Fri, 22 Sep 2017 20:50:00 +0000 Sandoz Proposed Biosimilar Adalimumab Matches Reference Medicine http://www.mdmag.com/medical-news/sandoz-proposed-biosimilar-adalimumab-matches-reference-medicine- http://www.mdmag.com/medical-news/sandoz-proposed-biosimilar-adalimumab-matches-reference-medicine- Thu, 14 Sep 2017 16:01:00 +0000 Upadacitinib Meets Endpoints in Second Phase 3 Study for Rheumatoid Arthritis http://www.mdmag.com/medical-news/upadacitinib-meets-endpoints-in-second-phase-3-study-for-rheumatoid-arthritis http://www.mdmag.com/medical-news/upadacitinib-meets-endpoints-in-second-phase-3-study-for-rheumatoid-arthritis Mon, 11 Sep 2017 19:51:00 +0000 FDA Panel Warns Against Approval of Janssen's Sirukumab http://www.mdmag.com/medical-news/fda-panel-warns-against-approval-of-janssens-sirukumab-for-rheumatoid-arthritis http://www.mdmag.com/medical-news/fda-panel-warns-against-approval-of-janssens-sirukumab-for-rheumatoid-arthritis Thu, 03 Aug 2017 02:56:00 +0000 The Connected Clinician's Top 5 Stories of the Week - July 28 http://www.mdmag.com/medical-news/the-connected-clinicians-top-5-stories-of-the-week--july-28 http://www.mdmag.com/medical-news/the-connected-clinicians-top-5-stories-of-the-week--july-28 Fri, 28 Jul 2017 19:30:00 +0000 FDA Rejects Lilly's Baricitinib http://www.mdmag.com/medical-news/fda-rejects-lillys-baricitinib http://www.mdmag.com/medical-news/fda-rejects-lillys-baricitinib Tue, 25 Jul 2017 14:01:00 +0000 Abatacept Wins Its Third FDA Indication http://www.mdmag.com/medical-news/abatacept-wins-its-third-fda-indication http://www.mdmag.com/medical-news/abatacept-wins-its-third-fda-indication Thu, 06 Jul 2017 13:14:10 +0000 Upadacitinib Meets Primary, Secondary Endpoints for RA Treatment http://www.mdmag.com/medical-news/upadacitinib-meets-primary-secondary-endpoints-for-ra-treatment http://www.mdmag.com/medical-news/upadacitinib-meets-primary-secondary-endpoints-for-ra-treatment Thu, 08 Jun 2017 14:26:32 +0000 Rheumatoid Arthritis Treatment Wins FDA Approval http://www.mdmag.com/product-news/rheumatoid-arthritis-treatment-wins-fda-approval http://www.mdmag.com/product-news/rheumatoid-arthritis-treatment-wins-fda-approval Tue, 23 May 2017 02:55:00 +0000 First Drug to Specifically Treat Giant Cell Arteritis Gains FDA Approval http://www.mdmag.com/product-news/first-drug-to-specifically-treat-giant-cell-arteritis-gains-fda-approval http://www.mdmag.com/product-news/first-drug-to-specifically-treat-giant-cell-arteritis-gains-fda-approval Mon, 22 May 2017 03:38:00 +0000 Diagnostic and Treatment Practices in Rheumatoid Arthritis http://www.mdmag.com/conference-coverage/aapa-2017/diagnostic-and-treatment-practices-in-rheumatoid-arthritis http://www.mdmag.com/conference-coverage/aapa-2017/diagnostic-and-treatment-practices-in-rheumatoid-arthritis Tue, 16 May 2017 10:13:00 +0000 Rewired Stem Cells Could Provide Their Own Arthritic Drug, Research Finds http://www.mdmag.com/medical-news/rewired-stem-cells-could-provide-their-own-arthritic-drug-research-finds http://www.mdmag.com/medical-news/rewired-stem-cells-could-provide-their-own-arthritic-drug-research-finds Wed, 10 May 2017 07:25:00 +0000 Pfizer Seeks to Expand Tofacitinib Approval to Include Psoriatic Arthritis http://www.mdmag.com/product-news/pfizer-seeks-to-expand-tofacitinib-approval-to-include-psoriatic-arthritis http://www.mdmag.com/product-news/pfizer-seeks-to-expand-tofacitinib-approval-to-include-psoriatic-arthritis Wed, 03 May 2017 04:26:00 +0000 FDA Approves Infliximab Biosimilar http://www.mdmag.com/product-news/fda-approves-infliximab-biosimilar http://www.mdmag.com/product-news/fda-approves-infliximab-biosimilar Fri, 21 Apr 2017 08:40:00 +0000 ACT-SOLO Study: Patients Receiving Tocilizumab Monotherapy Still Benefit http://www.mdmag.com/medical-news/act-solo-study-patients-receiving-tocilizumab-monotherapy-still-benefit http://www.mdmag.com/medical-news/act-solo-study-patients-receiving-tocilizumab-monotherapy-still-benefit Wed, 19 Apr 2017 08:20:00 +0000 Rigel Submits NDA for Fostamatinib http://www.mdmag.com/product-news/rigel-submits-nda-for-fostamatinib http://www.mdmag.com/product-news/rigel-submits-nda-for-fostamatinib Mon, 17 Apr 2017 09:56:00 +0000 Epidemiological Investigation of Rheumatoid Arthritis Links Manual Labor to the Disease http://www.mdmag.com/medical-news/epidemiological-investigation-of-rheumatoid-arthritis-links-manual-labor-to-the-disease http://www.mdmag.com/medical-news/epidemiological-investigation-of-rheumatoid-arthritis-links-manual-labor-to-the-disease Mon, 17 Apr 2017 08:44:00 +0000 FDA Rejects Lilly's Rheumatoid Arthritis Drug http://www.mdmag.com/product-news/fda-rejects-lillys-rheumatoid-arthritis-drug http://www.mdmag.com/product-news/fda-rejects-lillys-rheumatoid-arthritis-drug Fri, 14 Apr 2017 06:32:00 +0000 Impending Baricitinib Decision May Initiate New JAK Era for RA Treatment http://www.mdmag.com/medical-news/impending-baricitnib-decision-may-initiate-new-jak-era-for-ra-treatment http://www.mdmag.com/medical-news/impending-baricitnib-decision-may-initiate-new-jak-era-for-ra-treatment Thu, 13 Apr 2017 07:42:00 +0000 FUNCTION Trial: Sustained Results for RA with Tocilizumab Maintained Through 2 Years http://www.mdmag.com/medical-news/function-trial-sustained-results-for-ra-with-tocilizumab-maintained-through-2-years http://www.mdmag.com/medical-news/function-trial-sustained-results-for-ra-with-tocilizumab-maintained-through-2-years Tue, 11 Apr 2017 07:32:00 +0000 Study: Depression Can Exacerbate Rheumatoid Arthritis http://www.mdmag.com/medical-news/study-depression-can-exacerbate-rheumatoid-arthritis http://www.mdmag.com/medical-news/study-depression-can-exacerbate-rheumatoid-arthritis Tue, 11 Apr 2017 05:41:00 +0000 The Lipid Paradox: Why Are RA Patients with Low Cholesterol at Risk for CVD? http://www.mdmag.com/medical-news/the-lipid-paradox-why-are-ra-patients-with-low-cholesterol-at-risk-for-cvd http://www.mdmag.com/medical-news/the-lipid-paradox-why-are-ra-patients-with-low-cholesterol-at-risk-for-cvd Mon, 10 Apr 2017 06:31:00 +0000 The Lipid Paradox: Why Are RA Patients with Low Cholesterol at Risk for CVD? http://www.mdmag.com/medical-news/the-lipid-paradox-why-are-ra-patients-with-low-cholesterol-at-risk-for-cvd http://www.mdmag.com/medical-news/the-lipid-paradox-why-are-ra-patients-with-low-cholesterol-at-risk-for-cvd Mon, 10 Apr 2017 06:31:00 +0000 FDA Approves Dupilumab, a Potential Blockbuster for Atopic Dermatitis http://www.mdmag.com/product-news/fda-approves-dupilumab-a-potential-blockbuster-for-atopic-dermatitis http://www.mdmag.com/product-news/fda-approves-dupilumab-a-potential-blockbuster-for-atopic-dermatitis Tue, 28 Mar 2017 04:05:00 +0000 European Commission Approves Oral Rheumatoid Arthritis Treatment http://www.mdmag.com/product-news/european-commission-approves-oral-rheumatoid-arthritis-treatment http://www.mdmag.com/product-news/european-commission-approves-oral-rheumatoid-arthritis-treatment Mon, 27 Mar 2017 02:43:00 +0000 EU Commission Approves Drug for Select Adult, Pediatric Inflammatory Diseases http://www.mdmag.com/product-news/european-commission-approves-drug-for-select-adult-pediatric-inflammatory-diseases http://www.mdmag.com/product-news/european-commission-approves-drug-for-select-adult-pediatric-inflammatory-diseases Thu, 23 Mar 2017 09:12:00 +0000